XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2020
Dec. 31, 2019
ASSETS    
Cash and cash equivalents $ 26,684 $ 14,032
Marketable securities 8,207 11,125
Prepaid and other current assets 1,735 815
Total current assets 36,626 25,972
Property and equipment, net 83 100
Other assets 772 1,081
Total assets 37,481 27,153
Liabilities    
Accounts payable 592 1,490
Accrued liabilities 2,888 4,486
Total current liabilities 3,480 5,976
Other long-term liabilities 445 624
Total liabilities 3,925 6,600
Commitments and Contingencies
Stockholders' Equity    
Preferred stock, authorized, 20,000,000 shares Series B convertible redeemable preferred stock liquidation value, 0.001 share of common stock, $0.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at June 30, 2020 and December 31, 2019, respectively 0 0
Common stock, $0.001 par value, authorized 500,000,000 shares; issued and outstanding, 15,585,194 and 10,528,689 shares at June 30, 2020 and December 31, 2019, respectively 16 11
Additional paid-in capital 449,302 438,911
Treasury stock, at cost; 11,080 shares at June 30, 2020 and December 31, 2019 (708) (708)
Accumulated deficit (414,792) (417,400)
Accumulated other comprehensive (loss) income (7) 2
Total Caladrius Biosciences, Inc. stockholders' equity 33,811 20,816
Noncontrolling interests (255) (263)
Total stockholders' equity 33,556 20,553
Liabilities and Equity, Total $ 37,481 $ 27,153